APELLIS PHARMACEUTICALS

SYFOVRE

Manufacturer:

APELLIS PHARMACEUTICALS

Syfovre HCPCS:

J2781

HCPCS Code Descriptor:

Injection, pegcetacoplan, intravitreal, 1 mg

Category:

J Code

Syfovre NDCs:

73606-0020-01

Primary Type:

Opthalmic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravitreal

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Syfovre:

SYFOVRE is an Opthalmic drug manufactured by Apellis Pharma and administered via the intravitreal route of administration. The J Code: J2781 is aligned to the drug SYFOVRE.

SYFOVRE is a pepcetacoplan injection that is commonly used for the treatment of geographic atrophy as a secondary condition to age-related macular degeneration. Pepcetacoplan is composed of two pentadecapeptides and polyethylene glycol (PEG). SYFOVRE (J2781) works by inhibiting C3, the main protein in the complement cascade, to regulate an overactive complement cascade and potentially overactive immune system. SYFOVRE is often used to treat adults over the age of 65. Patient assistance for this medication can be found through the manufacturer, Apellis.

ACCESS PRICING AND MORE BY REGISTERING

J2781 Added Date:

October 1, 2023

J2781 Effective Date:

October 1, 2023

J2781 Termination Date:

HCPCS Active

Syfovre billing and coding information can be found through Apellis Pharmaceuticals at the link below:
Syfovre patient assistance information can be found through Apellis at the URL: https://apellis.com/our-products/
SYFOVRE prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for SYFOVRE. Please check back in a few weeks.